BMS, Pfizer, and AstraZeneca each made bold moves this week that signal how pharma is evolving. From deep direct-to-patient discounts and billion-dollar bets on obesity to a Supreme Court fight over Medicare pricing, the industry is rewriting its playbook. Access, affordability, and innovation are at the center of what comes next.

RNA therapies hold immense promise but bring fresh challenges in access, pricing, and reimbursement. As direct-to-consumer models emerge, the industry must rethink how innovation reaches patients—balancing high development costs with equitable access.